CTOs on the Move

Huyabio

www.huyabio.com

 
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.huyabio.com
  • 12531 High Bluff Drive Suite 138
    San Diego, CA USA 92130
  • Phone: 858.798.8800

Executives

Name Title Contact Details

Similar Companies

EMSAR

You can depend on us. Our mission is to provide quality equipment services and repairs to our valued customers across the U.S. and Canada.

Mobile Physician Services

Mobile Physician Services is a practice of doctors and nurse practitioners who make house calls to homebound patients. We specialize in the treatment of patients with complex medical needs. MPS is one of the only house call practices in the United Sta...

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Eddingpharm Group Co.

Eddingpharm Group Co. is a Carrboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.